UNSPSC 51432402: Moveltipril

This classification denotes an ace inhibitor with the molecular formula C19H30N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LQI0441316, chemically known as (-)-1-((2s)-3-mercapto-2-methylpropionyl)-l-proline, ester with n-(cyclohexyl-carbonyl)thio-d-alanine. but generally known as moveltipril, which bears US NIH Compound Identifier 5745793. European Medicines Agency schedules Moveltipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09078MIG.

UNSPSC 51432402 Moveltipril is a Commodity code covering emergency and acute-care medications procured by state and local health agencies, fire departments, and cooperative purchasing alliances for patient care and emergency medical services. State and local governments buy specific pharmaceutical products under this code — emergency cardiac and blood-pressure medications, OTC products, and injectable agents — through sealed-bid procurements, RFPs with multi-vendor frameworks, and cooperative purchasing vehicles. Issuing bodies include city fire rescue departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances administering contracts across participating state and local facilities. The work spans supply of manufactured pharmaceuticals with precise National Drug Codes, expiration-date guarantees, compliance with cGMP and FDA standards, Safety Data Sheets, and logistics including delivery timelines, pickup of expired stock, and distribution through authorized wholesalers.

Recent activity clusters in Florida and the multistate cooperative corridor (Minnesota, Oregon, and allied jurisdictions). The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) for Advanced Life Support Medications on April 24, 2026, with a due date of April 8, 2026 and an estimated contract value of $40,000.00, soliciting four specific medication line items for Tampa Fire Rescue with a Small Local Business Enterprise (SLBE) sheltered-market 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, awarding multiple contracts effective July 1, 2026, and requiring manufacturers to work through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC as authorized wholesalers. The Texas Health and Human Services Commission issued an exploratory Request for Information (RFI No. HHS0017013) on April 3, 2026 to gauge vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling potential future formal procurement.